GERALD WAGNER, PH.D. - Corporate Board Profile

STRATA Skin Sciences, Inc.

Filing Date	Source Excerpt
2006-04-18	Gerald Wagner, Ph.D. was appointed as a member of our board of directors in May 2005 and our acting Chief Operating Officer in January 2006. Since 2002, he has owned and operated Gerald Wagner Consulting LLC, an international consulting company specializing in: international project management; technology and application consulting; and company assessments. From March 1992 to September 2003, he was a Senior Vice President, Lab Testing Systems, at Bayer, Inc. Dr. Wagner received a Masters and Ph.D. in electro-mechanical design from Technical University, Darmstadt, Germany.
2007-04-20	Gerald Wagner, Ph.D. was appointed as a member of our Board of Directors in May 2005 and was our acting Chief Operating Officer from January 2006 until January 2007. ... Dr. Wagner's total compensation including consulting fees and director compensation was $594,489 in 2006.
2008-04-15	Gerald Wagner, Ph.D. was appointed as a member of our Board of Directors in May 2005. The compensation table shows he earned $73,800 in 2007.
2009-04-17	Gerald Wagner, Ph.D. was appointed as a member of our Board of Directors in May 2005 and was our acting Chief Operating Officer from January 2006 until January 2007. He currently serves as a consultant to the Company. Since 2002, he has owned and operated Gerald Wagner Consulting LLC, an international consulting company specializing in international project management, technology and application consulting, and company assessments. Dr. Wagner serves as a board member for IntegraGen S.A, Evry, France. From March 1992 to September 2003, he was a Senior Vice President, Lab Testing Systems, at Bayer, Inc. Dr. Wagner received a Masters and Ph.D. in electro-mechanical design from Technical University, Darmstadt, Germany.
2010-03-25	Gerald Wagner, Ph.D. was appointed as a member of our Board of Directors in May 2005 and was our acting Chief Operating Officer from January 2006 until January 2007. He currently serves as a consultant to the Company. For 2009 our non-employee directors received an annual fee of $10,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. The chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2009, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant. Dr. Wagner’s 2009 consulting fees related to obtaining FDA approval of MelaFind, and certain technical and competitive matters amounted to $30,000. Total compensation for Dr. Wagner was $86,875.
2011-03-24	Gerald Wagner, Ph.D. was appointed as a member of our Board of Directors in May 2005 and was our acting Chief Operating Officer from January 2006 until January 2007. For 2010 our non-employee directors received an annual fee of $15,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. In addition, the chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2010, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock in respect of their service as directors for that year. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant. Dr. Wagner’s 2010 consulting fees related to obtaining FDA approval of MelaFind, and certain technical and competitive matters amounted to $30,000.